Despite unprecedented events in public health and politics, the US Food and Drug Administration’s 2021 story about novel agent approvals hit some familiar (but nonetheless impressive) notes: another year of novel drug approval counts that would have been unfathomable in the first decade of the 2000s.
US FDA Novel Approvals Grew To 60 In 2021; CDER Cleared 50 New Agents, Turned Down 18
Approval total is one of FDA’s highest, but the large number of complete response letters obscures the staggering total of almost 80 new molecular entities and novel biologics that the agency acted on over the year.
More from Approvals
• By
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.
• By
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include four new products, one of which is Tivdak, Pfizer/Genmab’s treatment for previously treated recurrent or metastatic cervical cancer.
• By
Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.
• By
The African Medicines Agency is to appoint a director general and become operational at the end of this month.